SCHEMBL3089045

SCHEMBL3089045

Cc1nn(Cc2cccc(C#N)c2)c(C)c1-c1ccc(C#N)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 4/20 0.47
CYP11B2 P19099 2/20 0.46
CYP19A1 P11511 1/20 0.46
CYP11B1 P15538 1/20 0.46
ALDH1A1 P00352 1/20 0.45
DRD4 P21917 2/20 0.43
DRD3 P35462 2/20 0.43
DRD2 P14416 1/20 0.43
POLB P06746 1/20 0.42
GAA P10253 1/20 0.42
CREBBP Q92793 1/20 0.42
PTGDR2 Q9Y5Y4 1/20 0.41
ROCK2 O75116 1/20 0.41
TSHR P16473 1/20 0.40
BRD4 O60885 1/20 0.40
GRIN1 Q05586 1/20 0.39
GRIN2B Q13224 1/20 0.39
CRHR1 P34998 1/20 0.39
KMT2A Q03164 1/20 0.39
CYP1A2 P05177 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3085330 0.87 AR (0.50) ARCYP11B2CYP19A1CYP11B1POLB
SCHEMBL3086046 0.85 AR (0.46) ARCYP11B2CYP19A1CYP11B1ALDH1A1
SCHEMBL13308442 0.84 TSHR (0.42) CYP11B2CYP19A1CYP11B1ALDH1A1DRD4
SCHEMBL3086576 0.84 AR (0.53) ARCYP11B2CYP11B1PTGDR2GRIN1
SCHEMBL3084002 0.84 AR (0.48) ARGRIN1GRIN2B
SCHEMBL3086126 0.81 PI4KB (0.40) ARCYP11B2PTGDR2BRD4CRHR1
SCHEMBL3070156 0.81 SLC2A1 (0.53) ARCYP11B2CYP19A1CYP11B1ALDH1A1
SCHEMBL16832399 0.81 KDM4E (0.62) CYP11B2CYP19A1CYP11B1ALDH1A1DRD4
SCHEMBL13308508 0.79 AR (0.50) ARCYP11B2CYP19A1CYP11B1POLB
SCHEMBL3088592 0.79 AR (0.50) ARCYP11B2CYP19A1CYP11B1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101842357-A Substituted pyrazole derivatives TAKEDA PHARMACEUTICAL 2010-09-22 CN disclosed
US-20100227846-A1 SUBSTITUTED PYRAZOLE DERIVATIVE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-09 US disclosed
US-20100227846-A1 SUBSTITUTED PYRAZOLE DERIVATIVE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-09 US disclosed
US-20100227846-A1 SUBSTITUTED PYRAZOLE DERIVATIVE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-09 US disclosed
EP-2194045-A1 SUBSTITUTED PYRAZOLE DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2010-06-09 EP disclosed
EP-2194045-A1 SUBSTITUTED PYRAZOLE DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2010-06-09 EP disclosed
US-20090270359-A1 SUBSTITUTED PYRAZOLE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-29 US disclosed
US-20090270359-A1 SUBSTITUTED PYRAZOLE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-29 US disclosed
US-20090270359-A1 SUBSTITUTED PYRAZOLE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100227846-A1 SUBSTITUTED PYRAZOLE DERIVATIVE AR, NR5A1, NR3C2 AR 1/4885CYP11B2 13/4885CYP19A1 12/4885
US-20090270359-A1 SUBSTITUTED PYRAZOLE DERIVATIVES AR, NR5A1, NR3C2 AR 1/4885CYP11B2 13/4885CYP19A1 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.